References and Notes
- 1
Scriven EFV.
Turnbull K.
Chem. Rev.
1988,
88:
297
- 2
Smith SC.
Heathcock CH.
J. Org. Chem.
1992,
57:
6379
- 3
McDonald FE.
Danishefsky SJ.
J. Org. Chem.
1992,
57:
7001
-
4a
Ito M.
Koyakumaru K.
Takaya TH.
Synthesis
1995,
376
-
4b
Rao HSP.
Siva P.
Synth. Commun.
1994,
24:
549
-
4c
Alverez SG.
Fisher GB.
Singavam B.
Tetrahedron Lett.
1995,
36:
2567
-
4d
Molina P.
Diaz I.
Tarraga A.
Tetrahedron
1995,
51:
5617
-
4e
Ramesha AR.
Bhat S.
Chandrasekaran S.
J. Org. Chem.
1995,
60:
7682
-
4f
Capperucci A.
Degl’Innocenti A.
Funicello M.
Mauriello G.
Scafato P.
Spagnolo P.
J. Org. Chem.
1995,
60:
2254
-
4g
Kamal A.
Reddy BSP.
Reddy BSN.
Tetrahedron Lett.
1996,
37:
6803
-
4h
Huang Y.
Zhang Y.
Wang Y.
Tetrahedron Lett.
1997,
38:
1065
- 5
Molander GA.
Chem. Rev.
1992,
92:
29
-
6a
Kamal A.
Rao MV.
Laxman N.
Ramesh G.
Reddy GSK.
Curr. Med. Chem.: Anti-Cancer Agents
2002,
2:
215
-
6b
Kamal A.
Reddy KL.
Devaiah V.
Shankaraiah N.
Reddy DR.
Mini-Rev. Med. Chem.
2006,
6:
53
-
6c
Kamal A.
Reddy KL.
Devaiah V.
Shankaraiah N.
Rao MV.
Mini-Rev. Med. Chem.
2006,
6:
71
- 8
Thurston DE. In Molecular Aspects of Anticancer Drug-DNA Interactions
Vol. 1:
Neidle S.
Waring MJ.
The Macmillan Press Ltd;
London:
1993.
p.54
- 9
Thurston DE.
Bose DS.
Chem. Rev.
1994,
94:
433
- 7
Kamal A.
Shankaraiah N.
Reddy KL.
Devaiah V.
Tetrahedron Lett.
2006,
47:
4253
- 10
Kneko T.
Wong H.
Doyle TW.
Rose WC.
Brander WT.
J. Med. Chem.
1985,
28:
388
- 11
Blackburn BK.
Lee A.
Baier M.
Kohl B.
Olivero AG.
Matamoros R.
Robarge KD.
McDowell RS.
J. Med. Chem.
1997,
40:
717
- 12
Wright WB.
Brabander HJ.
Greenblatt EN.
Day IP.
Hardy RA.
J. Med. Chem.
1978,
21:
1087
- 13
Di Martino G.
Massa S.
Corelli F.
Pantaleoni G.
Fanini D.
Palumbo G.
Eur. J. Med. Chem.
1983,
18:
347
- 14
Karp GM.
Manfredi MC.
Guaciaro MA.
Ortlip CL.
Marc P.
Szamosi IT.
J. Agric. Food Chem.
1997,
45:
493
-
15a
Kaneko T.
Wong H.
Doyle TW.
J. Antibiotics
1984,
37:
300
-
15b
Kamal A.
Reddy BSP.
Reddy BSN.
Tetrahedron Lett.
1996,
37:
2281
-
15c
Jones GB.
Davey CL.
Jenkins TC.
Kamal A.
Kneale G.
Neidle S.
Webster GD.
Thurston DE.
Anti-Cancer Drug Des.
1990,
5:
249
-
15d
Kaneko T.
Wong H.
Doyle TW.
Tetrahedron Lett.
1983,
24:
5165
- 16
Kamal A.
Howard PW.
Reddy BSN.
Reddy BSP.
Thurston DE.
Tetrahedron
1997,
53:
3223
-
17a
Thurston DE.
Bose DS.
Chem. Rev.
1994,
94:
433
-
17b
Kamal A.
Rao MV.
Reddy BSN.
Khim. Geterotsikl. Soedin. (Chem. Heterocycl. Compd.)
1998,
1588
-
17c
Kamal A.
Rao NV.
Chem. Commun.
1996,
385
-
18a Carbateas PM. inventors; US 3,732,212.
; Chem. Abstr. 1973, 79, P42570x
-
18b Carbateas PM. inventors; US 3,763,183.
; Chem. Abstr. 1973, 79, P146567t
-
18c Carbateas PM. inventors; US 3,860,600.
; Chem. Abstr. 1975, 83, P58892x
-
18d
Reddy BSP.
PhD Thesis
Osmania University;
India:
1995.
19 General Procedure for Azido Reductions
The substituted aromatic azides were dissolved in MeCN (15 mL), BF3·OEt2 (2.0 equiv), NaI (50 mol%) was added and then solvent stirred at r.t. for 10-80 min to afford reductively cyclized products. The reaction mixture was quenched with aq Na2S2O3 followed by neutralization with aq NaHCO3 soln. The mixture was extracted with EtOAc (3 × 35 mL) and the combined organic extracts dried over anhyd Na2SO4. The solvent was evaporated under vacuum and the residue purified by column chromatography through SiO2 (60-120 mesh) eluting with EtOAc-hexane (yields as shown in Tables 1-3).
20 Selected Data
Compound 2h: 1H NMR (200 MHz, CDCl3): δ = 7.35-7.45 (m, 5 H), 7.22 (s, 1 H), 6.15 (s, 1 H), 5.47-5.90 (br s, 2 H), 5.20 (s, 2 H), 3.84 (s, 3 H), 3.83 (s, 3 H). MS (EI): m/z = 287 [M+].
Compound 4a: 1H NMR (200 MHz, CDCl3): δ = 8.05 (d, J = 7.43 Hz, 1 H), 7.79 (d, J = 4.46 Hz, 1 H), 7.53 (t, J = 6.69 Hz, 1 H), 7.28-7.38 (m, 2 H), 3.36-3.94 (m, 3 H), 2.26-2.38, (m, 2 H), 2.02-2.16 (m, 2 H). MS (EI): m/z = 200 [M+]. [α]D
26 +343 (c 0.4, CHCl3).
Compound 4b: 1H NMR (400 MHz, CDCl3): δ = 8.00-8.05 (m, 1 H), 7.00-7.80 (m, 1 H), 7.40-7.60 (m, 1 H), 7.20-7.30 (m, 1 H), 3.40-3.90 (m, 3 H), 1.90-2.50 (m, 7 H). MS (EI): m/z = 214 [M+].
Compound 4e: 1H NMR (200 MHz, DMSO-d
6): δ = 7.84 (d, 1 H, J = 7.32), 7.12-7.26 (m, 1 H), 6.95 (d, 1 H, J = 5.01 Hz), 6.70-7.80 (m, 2 H), 4.92 (d, 1 H, J = 4.81 Hz), 4.17-4.26 (m, 1 H), 4.02 (m, 1 H), 3.50-3.75 (m, 2 H), 1.95-2.10 (m, 1 H), 1.70-1.80 (m, 1 H). 13C NMR (50 MHz, DMSO-d
6): δ = 166.5, 150.2, 144.6, 133.5, 131.7, 131.4, 128.6, 125.2, 71.0, 56.6, 52.0, 39.5. MS (EI): m/z 216 [M+]. HRMS: m/z calcd for C12H12N2O2: 216.2358; found: 216.2361.
Compound 6a: 1H NMR (200 MHz, CDCl3): δ = 9.22 (br s, 1 H), 7.96-8.08 (d, 1 H, J = 8.03 Hz), 7.42-7.58 (t, 1 H, J = 8.03, 7.03 Hz), 7.21-7.28 (m, 1 H), 7.03-7.07 (d, 1 H, J = 8.03 Hz), 4.05-4.09 (d, 1 H, J = 6.57 Hz), 3.75-3.86 (m, 1 H), 3.51-3.65 (m, 1 H), 2.71-2.82 (m, 1 H), 1.85-2.15 (m, 3 H). MS (EI): m/z = 216 [M+]. HRMS: m/z calcd for C12H12N2O2: 216.2358; found: 216.2363.
Compound 6f: 1H NMR (200 MHz, DMSO-d
6): δ = 7.84 (d, 1 H, J = 7.3 Hz), 7.12-7.26 (m, 1 H), 6.95 (d, 1 H, J = 5.0 Hz), 6.70-6.80 (m, 2 H), 4.92 (d, 1 H, J = 4.8 Hz), 4.17-4.26 (m, 1 H), 4.02-4.10 (m, 1 H), 3.50-3.75 (m, 2 H), 1.95-2.10 (m, 1 H). 13C NMR (50 MHz, DMSO-d
6): δ = 166.5, 150.2, 144.6, 133.5, 131.7, 131.4, 128.6, 125.2, 71.0, 56.6, 52.0, 39.5. MS (EI): m/z = 232 [M+]. HRMS: m/z calcd for C12H12N2O3: 232.2352; found: 232.2358.
Compound 6j: 1H NMR (200 MHz, CDCl3): δ = 10.10 (s, 1 H), 7.26-7.40 (m, 6 H), 6.49 (s, 1 H), 5.10 (s, 2 H), 3.98-4.01 (d, 1 H, J = 6.44 Hz), 3.91 (s, 3 H), 3.65-3.75 (m, 1 H), 3.42-3.50 (m, 2 H), 2.65-2.75 (m, 1 H), 1.90-2.00 (m, 2 H). 13C NMR (50 MHz, DMSO-d
6): δ = 171.2, 166.5, 152.2, 146.6, 137.2, 131.4, 129.5, 128.6, 118.3, 113.4, 106.8, 71.0, 68.5, 56.6, 54.0, 35.8. MS (EI): m/z = 368 [M+]. HRMS: m/z calcd for C20H20N2O5: 368.3824; found: 368.3831.